Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BASF, Cargill and Novozymes Achieve Milestone in Bio-Based Acrylic Acid Process

Published: Thursday, July 11, 2013
Last Updated: Thursday, July 11, 2013
Bookmark and Share
Success in producing 3-hydroxypropionic acid for bio-based acrylic acid.

BASF, Cargill and Novozymes have announced the achievement of an important milestone in their joint development of technologies to produce acrylic acid from renewable raw materials by successfully demonstrating the production of 3-hydroxypropionic acid (3-HP) in pilot scale.

3-HP is a renewable-based building block and one possible chemical precursor to acrylic acid. The companies also have successfully established several technologies to dehydrate 3-HP to acrylic acid at lab scale.

This step in the process is critical since it is the foundation for production of acrylic acid. In August 2012, BASF, Cargill and Novozymes announced their joint agreement to develop a process for the conversion of renewable raw materials into a 100 percent bio-based acrylic acid.

“3-HP is a potential key raw material for the production of bio-based acrylic acid which is a precursor of superabsorbent polymers,” said Teressa Szelest, Senior Vice President Global Hygiene Business at BASF.

Szelest continued, “We still have a fair amount of work to do before the process is commercially ready, but this is a significant milestone and we are confident we can continue to the next level of scale-up for the entire process in 2014.”

Acrylic acid is a high-volume chemical that feeds into a broad range of products. BASF is the world’s largest producer of acrylic acid and has substantial capabilities in its production and downstream processing.

BASF plans initially to use the bio-based acrylic acid to manufacture superabsorbent polymers that can soak up large amounts of liquid and are used mainly in baby diapers and other hygiene products.

Presently, acrylic acid is produced by the oxidation of propylene derived from the refining of crude oil.

The companies’ joint project team combines world-class expertise in biotechnology, renewable feedstock, industrial scale fermentation, and in developing new chemical processes.

“Our three companies have assembled highly talented and experienced joint working teams for this project,” said Jack Staloch, Vice President of Biotechnology R&D at Cargill.

Staloch continued, “They’ve moved with speed and intensity, and have demonstrated great progress toward accomplishing our goals.”

“We have reached an important milestone by producing 3-HP in pilot scale,” said Rasmus von Gottberg, Vice President of Corporate Development and Business Creation at Novozymes. “We have shown that it is possible to make this key chemical building block from renewable raw materials in robust industrial conditions. Now the development work will continue towards commercialization.”

Superabsorbent polymers derived from bio-based acrylic acid will be a groundbreaking new offer to the market. Diapers made of such superabsorbent polymers could meet the demand of a significant and growing group of consumers in mature markets in particular.

They also may allow diaper producers to meet consumer demands, differentiate their products and contribute to their sustainability goals.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novozymes Biopharma Helps Innovative Dry Eye Therapy Move into Clinical Trials
A novel ophthalmic solution has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States.
Monday, May 20, 2013
Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!